Head-to-head evidence
STRO-004 vs Tisotumab Vedotin Humax-tf-adc
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: Tissue Factor (TF) · full Non-Small Cell Lung Cancer pipeline
STRO-004
Developed by Sutro Biopharma, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07227168 (registry estimate)
Tisotumab Vedotin Humax-tf-adc
Marketed by Pfizer and partners
NCT02001623 · Phase 1/2 · completed
This was an open-label, single-arm phase 1/2 safety study: 195 patients with advanced solid tumors all received tisotumab vedotin in dose-escalation cohorts (3–6 patients) and tumor-specific expansion cohorts, with no randomization, blinding, placebo, or active control. The primary endpoints were counts of treatment-emergent adverse events, so the results are descriptive safety/tolerability data only; there was no comparator arm or formal statistical comparison to establish efficacy. Because the design provides no controlled evidence of benefit, the evidence grade is weak.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: STRO-004's landscape · Tisotumab Vedotin Humax-tf-adc's landscape